ReviewJournal of clinical medicine2022
Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Crosstalk between circRNAs and the classic signaling pathways in IBD.RNA biology · 2026Review
- Polygonatum polysaccharide microspheres encapsulated living Clostridium butyricum for mucosal barrier repair and immune regulation.Journal of nanobiotechnology · 2026Article
- Efficacy and safety in the short-to-intermediate term of advanced combination therapy with upadacitinib for refractory Crohn's disease: real-world evidence from eastern China.Frontiers in medicine · 2026Article
- New Kids on the Block: IL-23 Inhibitors in IBD Management.Current gastroenterology reports · 2025Review
- Strengths, weaknesses, opportunities, and threats analysis of combination therapy for inflammatory bowel disease.World journal of gastroenterology · 2025Review
- DAMP-ing IBD: Extinguish the Fire and Prevent Smoldering.Digestive diseases and sciences · 2025Review
- Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it.World journal of gastroenterology · 2024Article
- Combination treatment of inflammatory bowel disease: Present status and future perspectives.World journal of gastroenterology · 2024Article
- Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus.Advances in therapy · 2024Article
- Horizon scanning: new and future therapies in the management of inflammatory bowel disease.eGastroenterology · 2023Review
- Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease.World journal of clinical cases · 2023Review
- Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease.Diseases (Basel, Switzerland) · 2022Article
- Special Issue "Clinical Advances in Chronic Intestinal Diseases Treatment".Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current medical treatment for inflammatory bowel disease (IBD) does not achieve 100% response rates, and a subset of refractory and severely ill patients have persistent active disease after being treated with all possible drug alternatives. The combination of two biological therapies (CoT) seems a reasonable alternative, and has been increasingly tested in very difficult cases. The present review suggests that CoT seems to be safe and effective for refractory and severely ill IBD patients. Ustekinumab plus vedolizumab and vedolizumab plus anti-TNF were the most used CoTs for Crohn's disease. For ulcerative colitis, the most used CoTs were vedolizumab plus anti-TNF and vedolizumab plus tofacitinib. The aforesaid CoTs have shown good efficacy and few adverse events have been reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.